GlassScriptPhysician profile
Jennifer Randall
NPI 1447944954
$4,565.82
in general payments reported to CMS, 2019-2025
22 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,139 · 2024: $2,200 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,526 · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,526.40 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.14 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $499.96 | 2023-2025 | Caplyta |
| Alkermes, INC. | $436.92 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Supernus Pharmaceuticals, INC. | $435.05 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $358.52 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $303.15 | 2023-2024 | Jornay Pm |
| Corium, LLC | $289.27 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $258.68 | 2023-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $234.79 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $230.96 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $172.27 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $127.82 | 2023-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $112.48 | 2023-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $112.41 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $108.30 | 2024-2025 | Dyanavel Xr, Onyda Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $65.54 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $52.67 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $44.22 | 2023-2024 | Trintellix |
| Noven Therapeutics, LLC | $28.07 | 2024-2025 | Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.85 | 2024 | Abilify Maintena |
| Tempus Ai, INC | $19.36 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.39 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.